検索結果

お知らせ | 千寿製薬株式会社

e formulation of Aibeta® combination eye drops（PDF） 2025年03月07日 Announcement of Licensing Agreement with Brill International（PDF） 2025年02月20日 Launch and Distribution of “MIEr for BeelineMED”（PDF） 2025...

产品开发方针 | 研究与开发 | 千寿制药株式会社

s T, et al. RNA-Seq-based transcriptome analysis of corneal endothelial cells derived from patients with Fuchs endothelial corneal dystrophy. Sci Rep. 2023;13(1):8647.  #6: Krachmer JH, Purcell JJ Jr,...

学会发表 | 研究与开发 | 千寿制药株式会社

開催地：Salt Lake City, Utah, United States of America Establishment of in vitro drug evaluation model with retinal ganglion cells from Leber’s hereditary optic neuropathy (LHON) patient-derived iPSC R.I...

論文投稿実績 | 研究開発活動 | 千寿製薬株式会社

愛媛大学医学部眼科学教室　2)千寿製薬株式会社　3)日野病院 あたらしい眼科42(12)：1566～1576 Efficacy and Safety of SJP-0132 in Patients with Dry Eye Disease: A Phase 2b Randomized, Double-Masked, Dose-Finding Study Yuichi Hori1, Tomoyuk...

nju is committed to obtaining marketing approval for the DED treatment SJP-0132 to provide patients with new options for alleviating the signs and symptoms of this disease. Mochida is dedicated to lev...